Intellia Therapeutics price target raised to $28 from $21 at Citizens

Citizens analyst Silvan Tuerkcan raised the firm’s price target on Intellia Therapeutics (NTLA) to $28 from $21 and keeps an Outperform rating on the shares. The FDA has lifted all clinical holds on Intellia’s nexiguran ziclumeran for transthyretin amyloid cardiomyopathy and transthyretin amyloid polyneuropathy after roughly four months, following agreement on updated exclusion criteria and protocol amendments, allowing Phase 3 enrollment to resume, the analyst tells investors in a research note. The decision was based on efficacy and safety data from approximately 650 enrolled patients, and although the data remain blinded to the company, the swift resolution suggests regulators viewed the overall risk-benefit profile as acceptable, the firm says.